Phillip Broadwith
As Business editor, my aim is to highlight to readers the exciting and innovative chemistry going on in the commercial sector, as well as keeping you abreast of trends and developments in the world of chemistry businesses.
From the point I left school, my aim was to join the pharmaceutical industry. A gap year and summer placements in company labs, and a PhD in organic synthesis followed.
But halfway through my PhD I entered a writing competition run by the Daily Telegraph. I managed to win – somewhat to my own surprise. That changed my perspective and made me think that I should consider writing more seriously as a career. I joined the Royal Society of Chemistry just before submitting my thesis, and luckily a position with Chemistry World came up a few months later. I sometimes miss the thrills (less so the spills) of lab work, but interacting with world-leading scientists and industrialists, as well as learning new things on a daily basis more than makes up for it.
Contact Info
- Email:
- broadwithp@rsc.org
OpinionIs Bayer regretting its Monsanto takeover?
Large damages in Roundup litigation have got investors questioning the move
BusinessAt least six dead in explosions in US and Russia
Blasts at silicones and fertiliser plants each leave three confirmed dead
OpinionShow me the data
Making industrial safety research more transparent benefits both companies and consumers
BusinessDeadly explosion at US chemical plant
Isobutylene tank explosion kills one and hospitalises two at KMCO plant in Crosby
BusinessWhat might Brexit mean for industry?
Questions hang over regulation, trade, talent and investment
OpinionDivergent reality
If the UK leaves the EU without a deal, the two will inevitably drift further apart
OpinionThinking differently about waste
Plastic and carbon emissions are valuable resources we can’t afford to discard
ReviewOrganic Chemistry for Babies
A chance for parents to start training the next generation of chemists
OpinionPushing the limits of patent protection
Some methods of extending exclusivity rights raise legal and ethical questions
OpinionPassing through checkpoints
A new breed of cancer treatments highlights what’s possible when industry concentrates its efforts
OpinionHas Crispr’s patent battle run its course?
As the originators duke it out in court, their patents are becoming increasingly irrelevant
BusinessCompany profile: Ellutia
Ellutia takes GC beyond the ‘box-in-the-lab’, with its customised chromatography
BusinessValeant relinquishes female libido drug
Struggling firm is returning Sprout Pharmaceuticals subsidiary to original shareholders to resolve dispute over marketing
BusinessGenerics firms Amneal and Impax to merge
Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
BusinessNovartis to buy AAA for radioligand cancer drugs
$3.9bn deal follows European approval of Advanced Accelerator Applications’ first-in-class radionuclide drug Lutathera
OpinionAre trade sanctions fair?
How much should markets be protected from cheaper imports? When does healthy competition become ‘dumping’?